Review: Protein misfolding in neurodegenerative diseases
Peer-reviewed publication on new strategies to target misfolded protein aggregates at various steps of protein production and processing…
A hallmark of neurodegenerative proteinopathies is the formation of misfolded protein aggregates, so therapeutic options are currently being explored to target different steps in the production and processing of proteins implicated in neurodegenerative disease. However, there are major challenges that impact the development of novel therapies, including incomplete knowledge of disease targets and a lack of biomarkers to monitor disease progression and therapeutic response.
This review paper is partly based on presentations at “Protein Misfolding—Implications and Strategies,” an open scientific satellite symposium held in conjunction with the Society for Neuroscience’s 45th Annual Meeting in 2015, sponsored and organized by Charles River.
Related content from this organisation
- Q&A: Integrated drug discovery panel – your questions answered
- Charles River adds ERS License to CRISPR/Cas9 service offering
- Charles River announces success of integrated discovery project with ENYO Pharma
- Whitepaper: In search of a disease-modifying agent for Parkinson’s disease: a discovery story
- Charles River Laboratories presents newly expanded capabilities at Neuroscience 2017